Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02055417 · ClinicalTrials.gov registry record · NA

Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention

A NA study of HIV, sponsored by University of Maryland, Baltimore.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT02055417: Completed NA study of HIV, sponsored by University of Maryland, Baltimore.

NCT02055417 is a NA study of HIV that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 50 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02055417, a NA study of HIV, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

In this 3-year study, the investigators will develop and pilot test an intervention called Personal Approaches to Treatment Choices for HIV (PATCH). PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART, using motivational interviewing (MI) techniques. The intervention will be targeted at HIV-positive African-American adults in inner-city Baltimore, Maryland who are suboptimally engaged in care and who endorse conspiracy beliefs about HIV or low readiness to begin ART. The specific aims are: (1) Develop and refine a manual for a brief MI intervention to support ART decision-making and reduce the likelihood of ART refusal: (2) Evaluate the feasibility and acceptability of implementing the PATCH intervention in a small sample of individuals who are African-American, recommended for ART but who are not current taking it, and who experience multiple barriers to ART adherence; and (3) Conduct a small randomized controlled pilot to test the potential efficacy of the PATCH intervention in producing positive attitudinal changes, including a reduction in conspiracy beliefs and perceived barriers to ART and stated readiness to begin ART.

Primary Outcome

Positive attitudinal changes includes a reduction in conspiracy beliefs and perceived barriers to ART. Attitudes will be assessed via questionnaires completed at the baseline, post treatment, and follow-up assessments.

Conditions Studied

Interventions

  • BEHAVIORAL Personal Approaches to Treatment Choices for HIV
  • BEHAVIORAL Stress Reduction Skills Program

Study Locations (1)

Maryland

  • University of Maryland School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-12
Est. Completion 2016-12
Phase NA
University of Maryland, Baltimore

560 total trials

What the finished NCT02055417 record still lists

NCT02055417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Personal Approaches to Treatment Choices for HIV is the first listed.

NCT02055417 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02055417 about?

NCT02055417 is a clinical study titled "Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention". In this 3-year study, the investigators will develop and pilot test an intervention called Personal Approaches to Treatment Choices for HIV (PATCH). PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART, using motiv...

What is the current status of trial NCT02055417?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2010-12. Estimated completion is 2016-12.

What conditions does trial NCT02055417 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT02055417?

The interventions under investigation include: Personal Approaches to Treatment Choices for HIV (BEHAVIORAL), Stress Reduction Skills Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT02055417?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02055417 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02055417's enrollment target sits among peer trials

50 219th of 303 higher than 73 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

  • NCT01746836 · 50 participants · Phase 2

    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02055417, the US trial registry maintained by the National Library of Medicine. NCT02055417 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.